Search results :

Metrodin

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: G03GA04

Side effects

Options: Show MedDRA Preferred Terms,   display only 20 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Abdominal cramps 14% x x x x x
Enlargement abdomen 2.7% - 13.9% x x x x x x x x x x x x
Headache postmarketing — 1.05% - 26.5% x x x x x x x x x x x x x x x x x x x x x x
Injection site bruising 9.7% x x x x x x x
Pelvic discomfort 8.26% x
Cramp muscle 6.67% x x x
Fullness abdominal 6.67% x x x
Breast pain female 4.2% - 6.1% x x x x x x x
Upper respiratory tract infection 1.7% - 11.9% x x x x
Ovarian hyperstimulation 3.5% - 7.23% x x x x x x x x x
Cyst 2.86% - 8.11% x x
Pharyngitis 2.5% - 7.23% x x x x x x x
Sinusitis 2% - 6.02% x x x x x x x x x x x
Breast disorder postmarketing, common x x x x x x
Nervous system disorder postmarketing, common x x x x x x x
Varicocele common x x x x x
Rhinitis 0.8% - 7.23% x x x x x x x x x
Pelvic pain female 1.7% - 7.1% x x
Dysmenorrhoea 2.5% - 6.1% x x x
Ovarian hyperstimulation syndrome very rare — 3.65% - 11.4% x x x x x x x x x x x x x x x
Injection site reaction postmarketing — 4% - 6.67% x x x x x x x x x x x x x x x x x x x x x
Abortion spontaneous 0.679% - 11.3% x x x x x x x x x x x x x x x x x x x
Foetal disorder 4.2% x
Gynaecomastia common, 3.33% x x x x x x x x x
Metrorrhagia postmarketing, 3.6% - 9.3% x x x x x x x x x x
Back pain 1.8% - 5.1% x x x x x x x x x x
Diarrhoea postmarketing — 0% - 7.6% x x x x x x x x x x x x x x x x x x
Flatulence 0% - 8.8% x x x x x x x x x
Nausea postmarketing — 0% - 13.6% x x x x x x x x x x x x x x x x x x x x x x
Ovarian cyst very common, 2.86% - 28.9% x x x x x x x x x x x x x x x x x x
Toothache 3.61% x x x x x
Migraine 3.61% x x x x x x x
Acne common, 0% - 6.67% x x x x x x x x x x x x x x x
Influenza-like symptoms 2.6% - 4.2% x x x x x x
Dermoid cyst 3.33% x x x x
Injection site inflammation 2.41% - 4.22% x x x x x x x x
Abdominal pain postmarketing — 0.537% - 23.2% x x x x x x x x x x x x x x x x x x x x x x
Pain postmarketing, 0% - 8.11% x x x x x x x x x x x x x x x x x
Abdominal discomfort postmarketing — 1.5% - 2.9% x x x x x x x x x
Weight increased common, 0% - 3.6% x x x x x x x
Ovarian disorder 1.7% - 8.11% x x x x x x
Urinary tract infection postmarketing, 0% - 4.4% x x x x x x
Rash postmarketing, 2.67% - 3.33% x x x x x x x x x x x x
Muscle spasms postmarketing, 2.67% x x
Vaginal discharge postmarketing, 2.67% x x x x
Spotting vaginal 2.67% x x x
Vomiting postmarketing — 0% - 2.7% x x x x x x x x x x
Mood swings 0% - 5.1% x x x x x
Leukorrhea 1.7% - 3.4% x x
Application site oedema 2.53% x x x x x x
Unspecified disorder of skin and subcutaneous tissue postmarketing, common x x x x x x x
Cough 1.7% - 2.6% x x x x x x x x
Cystitis 2.41% x x x x x x x
Dizziness 0% - 2.5% x x x x x x x x x x x
Dyspepsia 1.7% - 3.5% x x x x x x x
Body temperature increased 0% - 4.2% x x x x x x x x x x x x x x x x
Ulcerative stomatitis 2.41% x x x x x
Pollakiuria 2.41% x x x x x x
Uterine haemorrhage 2.41% x x x x
Viral infection 2.41% x x x x x x x x
Malaise 2.41% x x x x x x x x x x
Hot flush postmarketing, 0% - 5.71% x x x x x x x x x
Gynecological-related pain 2.41% x x x x x
Fatigue 2.26% x x x
Injection site pain 0.5% - 6.67% x x x x x x x x x x x x x x
Constipation postmarketing, 0% - 2.7% x x x x x x x x x x x x x
Abdominal pain lower 1.49% - 2.86% x x
Ectopic pregnancy 0.198% - 3.8% x x x x x x x x x x x x x x x x x x
Fungal infection 2% x x x
Pelvic pain postmarketing, 1.24% - 6.67% x x x x x x x
Menstrual disorder 0.9% - 2.5% x x
Uterine cervical lesion 0.9% - 2.5% x x
Genital candidiasis 0.9% - 2.5% x x
Vaginal haemorrhage postmarketing, 0% - 8.57% x x x x x x x x x x x x x x x x
Cervix disorder 0% - 2.86% x x x
Neck pain 0% - 2.7% x x x
Dehydration 0% - 2.7% x x x
Depression 0% - 2.7% x x x
Dermatitis exfoliative 0% - 2.7% x x x
Hypertension 0% - 2.7% x x x
Accidental injury 0% - 2.7% x x x
Abdominal distension postmarketing — 1.07% - 1.19% x x x x x x x
Breast tenderness postmarketing, 2% x x x x x x x x x x x
Infection postmarketing x x x
Connective tissue disorder postmarketing x x
Contusion postmarketing x x x x x x x x
Gastrointestinal disorder postmarketing x x x x x x x
Hypersensitivity very rare, postmarketing x x x x x x x x x x x x x x x
Nasopharyngitis postmarketing x x
Multiple pregnancy postmarketing x
Pruritus postmarketing x x x x x x x
Swelling postmarketing x x x x x x x x x x
Angiopathy postmarketing x x x x x
Redness postmarketing x x x x x x x x
Anaphylactoid reaction postmarketing x x x x x x x
Ovarian enlargement postmarketing x x x x x x x x x x x x x x x x x x x x
Infestation NOS postmarketing x x
Asthma very rare, postmarketing x x x x x x x
Thromboembolism very rare, postmarketing x x x x x x x x
Anaphylactic shock very rare x x x x
Immune system disorder very rare x x
Mediastinal disorder very rare x x x
Shock very rare x x
Congenital anomaly x x x x x x x x x x x x x x
Multiple congenital abnormalities x x
Abscess x
Alopecia x x x x
Anorexia x x
Anxiety x x x
Arthralgia x x x
Atelectasis x x x
Mental disorder x
Coagulopathy x
Bronchitis x x
Congestive cardiomyopathy x x
Chest pain x x x
Conjunctivitis x
Cryptorchism x x
Drug abuse x x x
Dyspnoea x x x x x x
Dysuria x
Eczema x
Oedema x x
Endocrine disorder x
Congenital eye disorder x
Fertilization x x x x x
Gastrooesophageal reflux disease x
Haematoma x x x
Peritoneal haemorrhage x x x x x x x x x x x x x x
Haemoptysis x x
Haemorrhage x x
Haemorrhoids x x
Genital herpes x
Herpes simplex x
Herpes zoster x x
Hip dislocation x x
Hydatidiform mole x
Hydrocephalus x x
Hypotension x x
Influenza x x
Arthropathy x
Calculus of kidney x
Premature labour x x x x x x x x x x x
Cramps of lower extremities x
Leukopenia x
Low back pain x
Systemic lupus erythematosus x x
Breast pain x x x
Melaena x
Menorrhagia x
Nasal congestion x
Neoplasm x x x x x x x x x x x
Nervousness x x x
Neutropenia x
Otitis media x
Palpitations x x
Paraesthesia x x
Pilonidal cyst x x x x
Pregnancy x x x x x
Pruritus genital x x
Acute respiratory distress syndrome x
Skin disorder x
Spermatocele x x
Sweating x
Syncope x
Tachycardia x x x x
Thirst x x
Thrombosis x
Tooth disorder x x x
Erythema x x x x x x x x
Urinary incontinence x
Urticaria x x x x x x x
Uterine disorder x
Vaginal itching x
Vaginal inflammation x x
Varicose vein x x
Syncope vasovagal x
Vulvovaginitis x
Chills x x x
Torsion of ovary x x x x x x
Blood urea increased x
Swelling face x x
Injection site haemorrhage x x
Pregnancy disorder x
Aspartate aminotransferase increased x
Dry skin x x x x
Uterine enlargement x x x
Uterine spasm x
Trisomy 18 x x
General symptom x
Abnormal faeces x
Upper limb fracture x
Distress x x
Myalgia x x
Tachypnoea x x x
Abdominal pain upper x
Discomfort x
Tenderness x
Ache x x x
Hyperemesis x
Upset stomach x
Reaction febrile x x x
Nipple pain x
Throat sore x
Sepsis x
Secondary hypogonadism x x
Blood bilirubin increased x
Induration x
Exacerbation of asthma x
Gastrointestinal symptom NOS x x
Anovulatory cycle x x
Dependence x
Ovarian pain x
Lymphadenopathy x x x
Injection site irritation x
Injection site induration x
Face oedema x
Cough increased x
Throat irritation x
Genital infection x
Adnexal torsion x x x x x x x x x x x x x x
Omphalocele x x
Blood and lymphatic system disorders x
Blood lactate dehydrogenase increased x
Local reaction x x x x x
Red blood cells semen positive x
Thromboembolic event x x x x
Pharyngolaryngeal pain x
Insomnia x
Ovarian neoplasm x x x x x x x x x x x x x x x x
Meningocele x x
Abdominal bloating x x x
Puerperal pyrexia x x x x x x x x x x
Loose stools x
Somnolence x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

FOLLITROPIN ALFA/BETA / FOLLISTIM AQ

Side effects:33
Source:FDA

Follitropin Beta / Follistim

Side effects:42
Source:FDA

FOLLITROPIN

Side effects:31
Source:FDA Structured Product Label

FOLLITROPIN ALFA/BETA / GONAL-F RFF PEN

Side effects:45
Source:FDA

FOLLITROPIN ALFA/BETA / GONAL-F

Side effects:47
Source:FDA

FOLLITROPIN ALFA/BETA / GONAL-F RFF PEN

Side effects:48
Source:FDA

FOLLITROPIN

Side effects:50
Source:FDA Structured Product Label

FOLLITROPIN

Side effects:50
Source:FDA Structured Product Label

follitropin alfa / Gonal-F

Side effects:77
Source:FDA

FOLLITROPIN

Side effects:79
Source:FDA Structured Product Label

FOLLITROPIN ALPHA / GONAL-F PEN

Side effects:42
Source:Health Canada

FOLLITROPIN ALPHA / GONAL-F

Side effects:45
Source:Health Canada

follitropin alfa / follitropin alfa

Side effects:30
Source:EMA

follitropin alfa / follitropin alfa

Side effects:30
Source:EMA

follitropin beta / follitropin beta

Side effects:39
Source:EMA

follitropin

Side effects:39
Source:FDA Structured Product Label

follitropin

Side effects:41
Source:FDA Structured Product Label

UROFOLLITROPIN / BRAVELLE

Side effects:51
Source:FDA

FOLLITROPIN

Side effects:62
Source:FDA Structured Product Label

UROFOLLITROPIN / BRAVELLE

Side effects:85
Source:Health Canada

FOLLITROPIN BETA / PUREGON

Side effects:109
Source:Health Canada

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label